Our Pricing

Is Orlistat Safe During Pregnancy? UK Clinical Guidance

Published: 11 September 2026

Orlistat during pregnancy is not recommended by UK prescribers or the MHRA due to insufficient safety data and the absence of proven benefit for pregnant women. Weight loss medications like orlistat are contraindicated during gestation because pregnancy requires adequate nutrition for foetal development, and orlistat reduces fat absorption—potentially affecting fat-soluble vitamin uptake critical for maternal and foetal health. This page explains the clinical rationale, regulatory position, and safe alternatives for weight management during pregnancy.

Why Orlistat During Pregnancy Is Contraindicated

Orlistat during pregnancy is contraindicated because it inhibits gastrointestinal lipase enzymes, reducing dietary fat absorption by approximately 30% [1]. During pregnancy, fat-soluble vitamins (A, D, E, and K) are essential for foetal organ development, bone mineralisation, and blood clotting. Orlistat may impair absorption of these vitamins, potentially leading to deficiencies that compromise both maternal and foetal health [2].

The MHRA and UK prescribing guidelines state that orlistat should not be used during pregnancy due to lack of adequate human data demonstrating safety. Animal reproduction studies have not shown teratogenic effects, but the absence of controlled trials in pregnant women means the risk cannot be quantified [3]. UK clinical practice prioritises the precautionary principle: no weight loss medication is recommended during gestation unless the benefit clearly outweighs the risk, which is not the case for orlistat.

Clinical Evidence on Orlistat During Pregnancy Use

Limited observational data exist on orlistat during pregnancy outcomes. A retrospective cohort study reviewing inadvertent orlistat exposure during early pregnancy found no significant increase in major congenital malformations compared to unexposed controls, but the sample size was small and the study authors emphasised that this does not establish safety [4]. The lack of large-scale, prospective trials means UK prescribers cannot confidently rule out harm.

Orlistat's mechanism—blocking pancreatic and gastric lipases—means it acts locally in the gastrointestinal tract with minimal systemic absorption (less than 1% of the dose reaches systemic circulation) [1]. However, even local action can reduce nutrient bioavailability, which is particularly concerning during pregnancy when maternal nutrient stores must support foetal growth. For this reason, orlistat during pregnancy remains off-label and inadvisable.

What If I Took Orlistat Before Knowing I Was Pregnant?

If you inadvertently took orlistat during pregnancy before confirming gestation, stop the medication immediately and contact your GP or midwife. Most inadvertent exposures occur in early pregnancy (first 4-6 weeks), and the available evidence does not suggest a high risk of harm, but your healthcare provider will want to monitor vitamin levels and foetal development via routine antenatal scans [4]. Do not continue orlistat once pregnancy is confirmed.

UK Regulatory Position on Orlistat During Pregnancy

The MHRA classifies orlistat as contraindicated during pregnancy. The Summary of Product Characteristics (SmPC) for orlistat states that it should not be used by pregnant women due to insufficient clinical data. This regulatory stance aligns with guidance from the British National Formulary (BNF) and NICE, which recommend discontinuing all weight loss medications prior to conception or immediately upon confirmation of pregnancy [3].

UK prescribers are required to screen for pregnancy before initiating orlistat therapy in women of childbearing potential. At Cured Pharmacy, our online clinical assessment includes a mandatory pregnancy question, and orlistat cannot be prescribed if you are pregnant, planning pregnancy, or breastfeeding. This safeguard ensures compliance with MHRA guidance and protects maternal-foetal health.

Safe Weight Management Alternatives to Orlistat During Pregnancy

Weight management during pregnancy should focus on balanced nutrition, appropriate gestational weight gain, and supervised physical activity rather than pharmacological intervention. The Royal College of Obstetricians and Gynaecologists (RCOG) recommends that women with obesity receive individualised dietary counselling and moderate exercise guidance, but not weight loss medications [5].

If you were taking orlistat before pregnancy, discuss your weight management goals with your midwife or obstetrician. They may refer you to a specialist dietitian who can create a pregnancy-safe eating plan that supports healthy weight gain (typically 5-9 kg for women with obesity) without restricting essential nutrients. Postpartum, orlistat can be resumed once breastfeeding has ceased and you have medical clearance.

Postpartum Resumption of Orlistat

Orlistat during pregnancy is contraindicated, but it may be resumed postpartum once you are no longer breastfeeding. Orlistat is excreted in breast milk in animal studies, and while human data are limited, UK guidance advises against use during lactation [3]. Once you have completed breastfeeding and received postnatal clearance from your GP, you can restart orlistat at £12.00 via Cured Pharmacy, subject to clinical assessment. Use code Weightlossnew for £20 off your first order.

Risks of Using Orlistat During Pregnancy

The primary risk of orlistat during pregnancy is nutrient malabsorption, particularly of fat-soluble vitamins. Vitamin A deficiency can impair foetal eye and organ development; vitamin D deficiency affects bone mineralisation and may increase the risk of rickets; vitamin E deficiency is linked to neurological complications; and vitamin K deficiency can cause bleeding disorders in the newborn [2].

Additionally, orlistat's gastrointestinal side effects—including oily stools, faecal urgency, and flatulence—can be distressing during pregnancy when digestive discomfort is already common. These side effects do not directly harm the foetus but can reduce quality of life and adherence to prenatal care. For these reasons, orlistat during pregnancy is not prescribed by UK clinicians.

What to Do If You Need Weight Management Support During Pregnancy

If you are concerned about weight gain during pregnancy or have obesity-related complications (such as gestational diabetes), speak to your midwife or GP rather than seeking orlistat during pregnancy. The NHS offers antenatal weight management services, including dietitian support and exercise programmes tailored to pregnant women [5].

After delivery and once you have stopped breastfeeding, you can consider restarting orlistat or exploring other weight loss treatments available at Cured Pharmacy, such as Wegovy or Saxenda (subject to clinical suitability). Our UK-registered prescribers will conduct a full assessment to ensure any treatment is safe and appropriate for your postpartum health status. All consultations are free, confidential, and completed online in under 3 minutes.

How Cured Pharmacy Supports Safe Prescribing

At Cured Pharmacy, every prescription request undergoes review by our UK-registered clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073). Our assessment explicitly screens for pregnancy and breastfeeding, ensuring orlistat during pregnancy is never prescribed. We are GPhC-registered (9012511) and supply only genuine, UK-licensed medicines. For any questions about weight management during or after pregnancy, call us on (+44) 116 4646009.

Scientific References

1. Guerciolini, R. (1997). Mode of action of orlistat. International Journal of Obesity, 21(Suppl 3), S12-S23. [accessed 11 September 2026]
2. Thorne-Lyman, A., & Fawzi, W. W. (2012). Vitamin A and carotenoids during pregnancy and maternal, neonatal and infant health outcomes: a systematic review and meta-analysis. Paediatric and Perinatal Epidemiology, 26(Suppl 1), 36-54. [accessed 11 September 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Orlistat: Summary of Product Characteristics. MHRA, London. [accessed 11 September 2026]
4. Perrio, M. J., Wilton, L. V., & Shakir, S. A. (2007). The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity, 15(11), 2712-2722. [accessed 11 September 2026]
5. Royal College of Obstetricians and Gynaecologists. (2018). Care of Women with Obesity in Pregnancy (Green-top Guideline No. 72). RCOG, London. [accessed 11 September 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.